Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03764293 · ClinicalTrials.gov registry record · Phase 3
A Study to Evaluate SHR-1210 in Combination With Apatinib as First-Line Therapy in Patients With Advanced HCC
A Phase 3 study of Locally Advanced or Metastatic and Unresectable HCC, sponsored by Jiangsu HengRui Medicine Co..
- Completed
- Registry status
- Phase 3
- Development phase
- 543
- Enrollment target
- 20
- Study locations
NCT03764293: Completed Phase 3 study of Locally Advanced or Metastatic and Unresectable HCC, sponsored by Jiangsu HengRui Medicine Co..
NCT03764293 is a Phase 3 study of Locally Advanced or Metastatic and Unresectable HCC that has completed, run by Jiangsu HengRui Medicine Co.. The registered enrollment target is 543 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (30% lower). The trial reports 20 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03764293, a Phase 3 study of Locally Advanced or Metastatic and Unresectable HCC, has completed, sponsored by Jiangsu HengRui Medicine Co..
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 543 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a randomized, open-label, international, multi-center, phase III trial to evaluate the efficacy and safety of SHR-1210 plus apatinib mesylate versus sorafenib as first-line therapy in patients with advanced HCC.
Primary Outcome
OS was defined as the time from randomization to death from any cause.
Conditions Studied
Interventions
- DRUG Sorafenib
- DRUG SHR-1210
- DRUG Apatinib
Study Locations (20)
Other
- Cliniques Universitaires de Bruxelles Hopital Erasme - Brussels
- Cliniques Universitaires Saint-Luc - Brussels
- UZA - Edegem
- AZ Maria Middelares - Ghent
- AZ Groeninge - Kortrijk
Anhui
- Anhui Provincal Cancer Hospital - Hefei
- Anhui Provincal Hospital - Hefei
- The First Affiliated Hospital Of Anhui Medical University - Hefei
- The Second Affiliated Hospital Of Anhui Medical University - Hefei
California
- Beverly Hills Cancer Center - Beverly Hills
- University of California San Diego (UCSD)-Moores Cancer Center - La Jolla
- University of California - Irvine - Orange
Texas
- The Center for Cancer and Blood Disorders - Fort Worth
- MD Anderson Cancer Center - Houston
- Renovatio Clinical - The Woodlands
Beijing Municipality
- Chinese Academy of Medical Sciences Cancer Hospital - Beijing
- Beijing cancer Hospital - Beijing
- Peking University International Hospital - Beijing
Maryland
- University of Maryland - Baltimore
New York
- Cornell University Weill Cornell Medical College - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 543 participants |
| Start Date | 2019-06-10 |
| Est. Completion | 2023-06-14 |
| Phase | Phase 3 |
What the finished NCT03764293 record still lists
NCT03764293 is an interventional study that assigns participants to a tested intervention. The registered 543 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (30% lower).
The record links to 1 condition, with Locally Advanced or Metastatic and Unresectable HCC appearing as the primary indexed condition, and to 3 interventions - of which Sorafenib is the first listed.
NCT03764293 names 20 study sites across 7 states, led by Other, Anhui, California.
Frequently Asked Questions
What is clinical trial NCT03764293 about?
NCT03764293 is a clinical study titled "A Study to Evaluate SHR-1210 in Combination With Apatinib as First-Line Therapy in Patients With Advanced HCC". This is a randomized, open-label, international, multi-center, phase III trial to evaluate the efficacy and safety of SHR-1210 plus apatinib mesylate versus sorafenib as first-line therapy in patients with advanced HCC.
What is the current status of trial NCT03764293?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 543 participants. The study started on 2019-06-10. Estimated completion is 2023-06-14.
What conditions does trial NCT03764293 study?
This clinical trial studies the following conditions: Locally Advanced or Metastatic and Unresectable HCC.
What interventions are being tested in trial NCT03764293?
The interventions under investigation include: Sorafenib (DRUG), SHR-1210 (DRUG), Apatinib (DRUG).
Who is sponsoring clinical trial NCT03764293?
This trial is sponsored by Jiangsu HengRui Medicine Co., which has 8 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03764293 being conducted?
This trial has 20 study locations across California, Maryland, New York, Texas, Anhui. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03764293's enrollment target sits among peer trials
543 694th of 2000 higher than 1,307 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT07294053 · 543 participants · NA
Sugary Drink Labeling Study
- NCT03127761 · 544 participants
Assessment of Allogeneic Hematopoietic Cell Transplantation in Medicare Beneficiaries With Multiple Myeloma
- NCT04378790 · 544 participants · Phase 3
A Randomized Trial to Evaluate Sequential vs Simultaneous Patching
- NCT06118502 · 544 participants · NA
A Clinical Trial of Adaptive Treatment for Early Smoking Cessation Relapse
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI